Abstract
AKT (also known as PKB) plays a central role in a variety of cellular processes including cell growth, motility and survival in both normal and tumor cells. The AKT pathway is also instrumental in epithelial mesenchymal transitions (EMT) and angiogenesis during tumorigenesis. AKT functions as a cardinal nodal point for transducing extracellular (growth factors including insulin, IGF-1 and EGF ) and intracellular (such as mutated/activated receptor tyrosine kinases, PTEN, Ras and Src) signals. It is positively regulated by phosphatidylinositol 3-kinase and inhibited by phosphatase PTEN. Deregulation of the PI3K/PTEN/AKT pathway is one of the most common altered pathways in human malignancy. In the past few years, significant advances have been made in the understanding of AKT signaling in human oncogenesis and the development of small molecule inhibitor of AKT pathway. Here, we will discuss the regulation and function of AKT as well as targeting AKT for anti-cancer drug discovery.
Keywords: Akt, serine/threonine kinase, oncogene, signal transduction, anti-tumor target, small molecule inhibitor
Current Cancer Drug Targets
Title: Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Volume: 8 Issue: 1
Author(s): Lu-Hai Wang, George Z. Cheng, Sungman Park, Shaokun Shu, Lili He, William Kong, Weizhou Zhang, Zengqiang Yuan and Jin Q. Cheng
Affiliation:
Keywords: Akt, serine/threonine kinase, oncogene, signal transduction, anti-tumor target, small molecule inhibitor
Abstract: AKT (also known as PKB) plays a central role in a variety of cellular processes including cell growth, motility and survival in both normal and tumor cells. The AKT pathway is also instrumental in epithelial mesenchymal transitions (EMT) and angiogenesis during tumorigenesis. AKT functions as a cardinal nodal point for transducing extracellular (growth factors including insulin, IGF-1 and EGF ) and intracellular (such as mutated/activated receptor tyrosine kinases, PTEN, Ras and Src) signals. It is positively regulated by phosphatidylinositol 3-kinase and inhibited by phosphatase PTEN. Deregulation of the PI3K/PTEN/AKT pathway is one of the most common altered pathways in human malignancy. In the past few years, significant advances have been made in the understanding of AKT signaling in human oncogenesis and the development of small molecule inhibitor of AKT pathway. Here, we will discuss the regulation and function of AKT as well as targeting AKT for anti-cancer drug discovery.
Export Options
About this article
Cite this article as:
Wang Lu-Hai, Cheng Z. George, Park Sungman, Shu Shaokun, He Lili, Kong William, Zhang Weizhou, Yuan Zengqiang and Cheng Q. Jin, Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery, Current Cancer Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/156800908783497159
DOI https://dx.doi.org/10.2174/156800908783497159 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response
Current Cancer Drug Targets Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology TGR5 as a Therapeutic Target for Treating Obesity
Current Topics in Medicinal Chemistry Polymeric Nanoparticles of Aromatase Inhibitors: A Comprehensive Review
Current Pharmaceutical Design The Delicate Balance between the Good and the Bad IL-1 Proinflammatory Effects in Endometriosis
Current Medicinal Chemistry Telomerase Inhibitors as Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Bone Disease - Current Knowledge and Future Prospects
Current Genomics Cancer Diagnosis Through IsomiR Expression with Machine Learning Method
Current Bioinformatics Meet the Editorial Board
Current Drug Targets The Endocrine Regulation of Stem Cells: Physiological Importance and Pharmacological Potentials for Cell-Based Therapy
Current Stem Cell Research & Therapy Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design